All News

PSS.hands_.Raynauds.jpg (keep)

FDA Invites Patient Input on Systemic Sclerosis Drug Development

d Jack Cush, MD

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Read Article
PsA.Hands_.jpg

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

d Jack Cush, MD

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

Read Article
pain.jpg

Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction

d Jack Cush, MD

JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

d Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
Muscle (keep)

Immune Necrotizing Myopathy

d Jack Cush, MD

A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.

Read Article
Telemedicine.MD.Computer.phone (keep)

Telemedicine Outcomes in RA Care

d Jack Cush, MD

A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).

Read Article
FDA.jpg (keep)

FDA Hearing on COVID-19 Vaccines

d Jack Cush, MD

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

Read Article
Barer-Flood Prize Headshot of Canadian Instit of Health has awarded Dr. Peter Tugwell Barer-Flood Prize, recognizing and exceptional career with a substantial impact on health care policy research, policy, delivery. He is a founding member of Cochrane . https://t.co/qxqUrdEFYz https://t.co/HOuLw4DxP3

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoantibodies can be found in COVID-19 ptas (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT) https://t.co/kN6hVMiNt3 https://t.co/4yNJJhOxXP

Links:

Dr. John Cush RheumNow ( View Tweet)

ACTIV-1 run by the ⁦@NIH⁩ will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?

Links:

Peter Nash drpnash ( View Tweet)

New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)

Dr. John Cush RheumNow ( View Tweet)

Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37

Links:

Dr. John Cush RheumNow ( View Tweet)

PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA

Links:

Dr. John Cush RheumNow ( View Tweet)

Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful iTunes https://t.co/FHJv01Sb3a SoundCloud https://t.co/fceBeXGu09

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Back Talk: Taking Calls ^ Questions from Listeners - watch it here>https://t.co/KuTtu5JawO or listen to the Podcast on iTunes> https://t.co/FHJv01AAbC OR SoundCloud> https://t.co/ICukowi11u

Links:

Dr. John Cush RheumNow ( View Tweet)

Population study of 11 million, shows incidence of OPTIC NEURITIS is 3.7 /100K Pt-Yrs. Strongest association with multiple sclerosis (MS) and weaker associations with Behçet disease, sarcoidosis, and Sjögren syndrome. https://t.co/LVw0fcq1F1

Links:

Dr. John Cush RheumNow ( View Tweet)

Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Links:

Dr. John Cush RheumNow ( View Tweet)

How are you consuming Virtual CME Rheumatology conferences

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×